Literature DB >> 2251289

A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

V K Chaudhary1, M G Gallo, D J FitzGerald, I Pastan.   

Abstract

To kill human or primate cells expressing the p55 subunit of the interleukin 2 receptor, we have constructed a single-chain immunotoxin. DNA sequences encoding the first 388 amino acids of diphtheria toxin (DT) were fused to DNA elements encoding the antigen-binding portion (variable region or Fv) of the anti-Tac monoclonal antibody. The antigen-binding portion consists of 116 amino acids of the heavy-chain variable region connected by a 15-amino acid linker to 106 amino acids of the variable region of the light chain. The single-chain immunotoxin DT388-anti-Tac(Fv) was expressed in Escherichia coli and found in inclusion bodies. The monomeric form was then purified to near homogeneity with a high yield (3-5 mg/liter). Monomeric DT388-anti-Tac(Fv) was highly cytotoxic to cell lines bearing the p55 subunit of the human interleukin 2 receptor but not to cells without this subunit. DT388-anti-Tac(Fv) was also very effective in killing proliferating human T cells produced in a mixed leukocyte reaction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251289      PMCID: PMC55192          DOI: 10.1073/pnas.87.23.9491

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.

Authors:  D P Williams; C E Snider; T B Strom; J R Murphy
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

2.  Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.

Authors:  D P Williams; K Parker; P Bacha; W Bishai; M Borowski; F Genbauffe; T B Strom; J R Murphy
Journal:  Protein Eng       Date:  1987-12

3.  Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.

Authors:  T Kiyokawa; K Shirono; T Hattori; H Nishimura; K Yamaguchi; J C Nichols; T B Strom; J R Murphy; K Takatsuki
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

Review 4.  Redesigning nature's poisons to create anti-tumor reagents.

Authors:  E S Vitetta; R J Fulton; R D May; M Till; J W Uhr
Journal:  Science       Date:  1987-11-20       Impact factor: 47.728

5.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

Review 6.  Pseudomonas exotoxin: chimeric toxins.

Authors:  I Pastan; D FitzGerald
Journal:  J Biol Chem       Date:  1989-09-15       Impact factor: 5.486

7.  Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.

Authors:  V K Chaudhary; D J FitzGerald; S Adhya; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 12.779

8.  Cardiac allograft survival in mice treated with IL-2-PE40.

Authors:  H Lorberboum-Galski; L V Barrett; R L Kirkman; M Ogata; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 12.779

9.  Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.

Authors:  J P Case; H Lorberboum-Galski; R Lafyatis; D FitzGerald; R L Wilder; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 12.779

10.  Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.

Authors:  C B Siegall; V K Chaudhary; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 12.779

View more
  13 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 2.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 3.  Antibodies in the study of multiple drug resistance.

Authors:  Y Heike; T Tsuruo
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 4.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

Review 5.  Antigen recognition and targeted delivery by the single-chain Fv.

Authors:  J S Huston; M S Tai; J McCartney; P Keck; H Oppermann
Journal:  Cell Biophys       Date:  1993 Jan-Jun

Review 6.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

7.  B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

Authors:  U Brinkmann; L H Pai; D J FitzGerald; M Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 12.779

8.  A circularly permuted recombinant interleukin 4 toxin with increased activity.

Authors:  R J Kreitman; R K Puri; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 12.779

9.  Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor.

Authors:  R J Kreitman; I Pastan
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.766

Review 10.  Saporin-S6: a useful tool in cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Daniele Mercatelli; Maria Giulia Battelli; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2013-10-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.